par Payen, Marie-Christine 
;Van Vooren, Jean-Paul ;Vandenberg, Olivier ;Clumeck, Nathan ;De Wit, Stéphane
Référence Epidemiology and infection, 145, 7, page (1368-1373)
Publication Publié, 2017-05
;Van Vooren, Jean-Paul ;Vandenberg, Olivier ;Clumeck, Nathan ;De Wit, Stéphane Référence Epidemiology and infection, 145, 7, page (1368-1373)
Publication Publié, 2017-05
Article révisé par les pairs
| Résumé : | Tuberculosis (TB) remains a threat to public health and is the second cause of death due to a single infectious agent after HIV/AIDS. The worldwide distribution of TB is heterogeneous. The incidence is decreasing in most high-income regions, but the situation remains worrying in many parts of the world. The emergence of Mycobacterium tuberculosis strains resistant to key agents used in treatment (rifampin and isoniazid) contributes to TB transmission around the world. To achieve TB elimination, both high and low endemic countries must upscale their efforts to decrease disease transmission and improve cure rates. Management of drug-resistant TB is of particular importance. In this paper, we discuss the different models of care of multidrug-resistant TB (MDR-TB), the ethical considerations and the specific constraints present in high income countries. The management model chosen by the Belgian TB specialists in accordance with public health authorities as well as building of a specific MDR/XDR-TB isolation unit are also discussed. |
